Anebulo Pharmaceuticals, Inc. ( (ANEB) ) has released its Q1 earnings. Here is a breakdown of the information Anebulo Pharmaceuticals, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cannabis-induced toxicity, particularly in pediatric patients. In its recent earnings report, Anebulo highlighted the commencement of a Phase 1 clinical trial for an intravenous formulation of its lead drug candidate, selonabant, aimed at treating acute cannabis-induced toxicity in children. The company also received a significant grant from the National Institute on Drug Abuse to support this study. Financially, Anebulo reported operating expenses of $2.3 million and a net loss of $2.2 million for the first quarter of fiscal year 2026, with cash reserves of $10.4 million. Looking ahead, Anebulo is focused on advancing its selonabant IV formulation and exploring strategic alternatives, including a potential reverse stock split, as it aims to address the unmet need for treatments in cannabis toxicity, particularly in children.